PT Brigit Biofarmaka Technologi Tbk (IDX:OBAT)
Indonesia
· Delayed Price · Currency is IDR 334.00
0.00 (0.00%)
Last updated: Apr 29, 2026, 2:45 PM WIB
IDX:OBAT Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 160,118 | 120,627 | 56,930 | 38,496 | 37,853 |
| Revenue Growth (YoY) | 32.74% | 111.89% | 47.89% | 1.70% | - |
| Cost of Revenue | 98,437 | 64,206 | 34,578 | 19,022 | 14,872 |
| Gross Profit | 61,681 | 56,421 | 22,352 | 19,474 | 22,981 |
| Selling, General & Admin | 28,761 | 18,532 | 7,751 | 5,752 | 4,498 |
| Other Operating Expenses | 356.88 | 110.26 | 94.21 | 110.23 | 188.84 |
| Operating Expenses | 29,118 | 18,643 | 7,845 | 5,862 | 4,687 |
| Operating Income | 32,563 | 37,778 | 14,507 | 13,611 | 18,294 |
| Interest Expense | -1,832 | -1,381 | -1,253 | -845.28 | -279.34 |
| Interest & Investment Income | 1,509 | 2,674 | 1,822 | 1,369 | 750.66 |
| Earnings From Equity Investments | 495 | 406.25 | -250.26 | - | - |
| Other Non Operating Income (Expenses) | 117.57 | 52.54 | -1.45 | -2.61 | 1.74 |
| EBT Excluding Unusual Items | 32,852 | 39,531 | 14,824 | 14,133 | 18,767 |
| Asset Writedown | - | -3.83 | -66.98 | -2.97 | -7.76 |
| Other Unusual Items | - | - | 337.11 | 816.75 | 731.4 |
| Pretax Income | 32,852 | 39,527 | 15,094 | 14,946 | 19,491 |
| Income Tax Expense | 7,270 | 9,028 | 3,186 | 3,322 | 4,184 |
| Earnings From Continuing Operations | 25,582 | 30,499 | 11,908 | 11,625 | 15,307 |
| Minority Interest in Earnings | -2,940 | -1,073 | 65.94 | 759.76 | 342.69 |
| Net Income | 22,642 | 29,426 | 11,974 | 12,384 | 15,649 |
| Net Income to Common | 22,642 | 29,426 | 11,974 | 12,384 | 15,649 |
| Net Income Growth | -23.05% | 145.75% | -3.32% | -20.86% | - |
| Shares Outstanding (Basic) | 600 | 600 | 430 | 463 | 463 |
| Shares Outstanding (Diluted) | 600 | 600 | 430 | 463 | 463 |
| Shares Change (YoY) | - | 39.53% | -7.13% | - | - |
| EPS (Basic) | 37.74 | 49.04 | 27.85 | 26.75 | 33.80 |
| EPS (Diluted) | 37.74 | 49.04 | 27.85 | 26.75 | 33.80 |
| EPS Growth | -23.05% | 76.12% | 4.10% | -20.86% | - |
| Free Cash Flow | 3,204 | 6,355 | 6,528 | 7,148 | 14,908 |
| Free Cash Flow Per Share | 5.34 | 10.59 | 15.18 | 15.44 | 32.20 |
| Dividend Per Share | - | 22.370 | 16.950 | 32.400 | 17.280 |
| Dividend Growth | - | 31.98% | -47.69% | 87.50% | - |
| Gross Margin | 38.52% | 46.77% | 39.26% | 50.59% | 60.71% |
| Operating Margin | 20.34% | 31.32% | 25.48% | 35.36% | 48.33% |
| Profit Margin | 14.14% | 24.39% | 21.03% | 32.17% | 41.34% |
| Free Cash Flow Margin | 2.00% | 5.27% | 11.47% | 18.57% | 39.38% |
| EBITDA | 32,799 | 39,966 | 16,582 | 14,875 | 19,026 |
| EBITDA Margin | 20.48% | 33.13% | 29.13% | 38.64% | 50.26% |
| D&A For EBITDA | 236.81 | 2,188 | 2,075 | 1,263 | 731.94 |
| EBIT | 32,563 | 37,778 | 14,507 | 13,611 | 18,294 |
| EBIT Margin | 20.34% | 31.32% | 25.48% | 35.36% | 48.33% |
| Effective Tax Rate | 22.13% | 22.84% | 21.11% | 22.23% | 21.47% |
Source: S&P Capital IQ. Standard template. Financial Sources.